0000000001227723

AUTHOR

L. E. Weimer

showing 4 related works from this author

Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluat…

2017

Background: Few data are available on the virological and clinical outcomes of advanced liver disease patients retreated after first-line DAA failure. Aim: To evaluate DAA failure incidence and the retreatment clinical impact in patients treated in the advanced liver disease stage. Methods: Data on HCV genotype, liver disease severity, and first and second line DAA regimens were prospectively collected in consecutive patients who reached the 12-week post-treatment and retreatment evaluations from January 2015 to December 2016 in 23 of the PITER network centers. Results: Among 3,830 patients with advanced fibrosis (F3) or cirrhosis, 139 (3.6%) failed to achieve SVR. Genotype 3, bilirubin lev…

SimeprevirMaleGenetics and Molecular Biology (all)HepacivirusPediatricsGastroenterologyBiochemistry0302 clinical medicineAnimal Cells80 and overBileMedicinePublic and Occupational HealthProspective Studieslcsh:ScienceAged 80 and overAdult; Aged; Aged 80 and over; Antiviral Agents; Drug Therapy Combination; Female; Hepatitis C; Humans; Incidence; Liver Diseases; Male; Middle Aged; Prospective Studies; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Liver DiseaseIncidenceLiver DiseasesChild HealthBloodCirrhosisPhysical SciencesRegression Analysis030211 gastroenterology & hepatologyDrug Therapy CombinationCellular TypesStatistics (Mathematics)Humanmedicine.medical_specialtyGastroenterology and HepatologyMicrobiologyAntiviral Agents03 medical and health sciencesDrug TherapyHumansStatistical MethodsAgedBlood CellsBiochemistry Genetics and Molecular Biology (all)Flaviviruseslcsh:ROrganismsBiology and Life Sciencesmedicine.diseaseRegimenProspective Studie030104 developmental biologychemistryAgricultural and Biological Sciences (all)lcsh:QMathematicsDevelopmental BiologyRNA viruses0301 basic medicineDAA HCV resistanceSofosbuvirPhysiologylcsh:MedicineLiver diseasechemistry.chemical_compoundMathematical and Statistical TechniquesMedicine and Health SciencesPathology and laboratory medicineMultidisciplinaryHepatitis C virusHepatitis CMedical microbiologyMiddle AgedHepatitis CBody FluidsVirusesCombinationFemaleAnatomyPathogensResearch Articlemedicine.drugPlateletsLedipasvirAdultDaclatasvirSettore MED/12 - GASTROENTEROLOGIAHCV liver diseases Cirrhosis DAA failureResearch and Analysis MethodsInternal medicineAntiviral Agentbusiness.industryViral pathogensBilirubinCell BiologyFibrosisHepatitis virusesMicrobial pathogensSurgeryLiver functionbusiness
researchProduct

Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S01688278173…

2018

It has come to our attention that the PITER framework investigator, Alessandro Federico, was incorrectly listed as F. Alessandro in the original manuscript. Please note that the correct name of this author is Alessandro Federico (2nd University of Naples). The correct list of PITER investigators is in the footnote below.

HepatologyHepatitis B; EASL guidelines; Treatment; Interferon; Entecavir; Tenofovir; TAF; HBsAg; Hepatocellular carcinoma; HBV DNA; HBV reactivation; Mother to child transmissionHepatocellular carcinomaHBV reactivationEASL guidelinesHepatitis BEntecavirTreatmentHBsAgTAFHBV DNAMother to child transmissionInterferonTenofovirEASL guideline
researchProduct

Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

2017

Background & Aims Premenopausal women who are HCV positive (HCV+) have failing ovarian function, which is likely to impact their fertility. Thus, we investigated the reproductive history, risk of infertility, and pregnancy outcomes in women of childbearing age who were HCV+. Methods Three different groups were studied: (1) Clinical cohort: 100 women who were HCV+ and also had chronic liver disease (CLD), age matched with 50 women who were HBV+ with CLD and with 100 healthy women; all women were consecutively observed in three gastroenterology units in hospitals in Italy; (2) 1,998 women who were HCV+ and enrolled in the Italian Platform for the Study of Viral Hepatitis Therapies (PITER)…

Anti-Mullerian hormone; Antiviral therapy; HBV; HCV; Sustained viral response; HepatologyInfertilitymedicine.medical_specialtySustained viral responsemedia_common.quotation_subjectFertilityAnti-Müllerian hormoneAntiviral therapyMiscarriage03 medical and health sciences0302 clinical medicineHBVMedicineProspective cohort studymedia_commonGynecologyAnti-Müllerian hormone Antiviral therapy HBV HCV Sustained viral response030219 obstetrics & reproductive medicineHepatologybusiness.industryObstetricsAnti-Müllerian hormone; Antiviral therapy; HBV; HCV; Sustained viral responseAnti-Mullerian hormonemedicine.diseaseAnti-Müllerian hormoneGestational diabetesCohortHCV030211 gastroenterology & hepatologyAnti-Müllerian hormone; Antiviral therapy; HBV; HCV; Sustained viral response; HepatologybusinessLive birthCell aging
researchProduct

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

2019

OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…

Liver CirrhosisPediatricsTime FactorsSettore MED/09 - Medicina InternaNational Health ProgramsERADICATIONOUTBREAKantiviral treatment anti HCV economic consequencesHepacivirusLIVER FIBROSISSeverity of Illness IndexHealth Services AccessibilityCOST-EFFECTIVENESSIndirect costs0302 clinical medicineEpidemiologyvirus infection030212 general & internal medicinehealth care economics and organizationscost effectiveness030503 health policy & servicesHealth PolicyHealth services researchhealthHepatitis CHepatitis CMarkov Chainschronic hepatitis C virus infection fibrosis progression cost effectiveness liver fibrosisItalyPharmacology; Health Policy; Public Health Environmental and Occupational HealthCohortSettore SECS-P/03 - Scienza delle FinanzeDisease ProgressionPublic Health0305 other medical scienceViral hepatitisAnti-HCV antiviral treatmentCHRONIC HEPATITIS-Cmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAVIRUS-INFECTIONAntiviral AgentsNO03 medical and health sciencesCost SavingsAntiviral Agents; Cost Savings; Disease Progression; Genotype; Health Policy; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Markov Chains; National Health Programs; Severity of Illness Index; Time FactorsmedicineMANAGEMENTHumanschronic hepatitis CINDUCED DISEASESMETAANALYSISPharmacologyHealth economicsbusiness.industryPublic healthEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthmedicine.diseaseFIBROSIS PROGRESSIONbusiness
researchProduct